Stoke Therapeutics logo


Stoke Therapeutics


Earnings Summary

Net Profits


Net Profits:

Stoke Therapeutics’s net profit fell -137.27% since last year same period to $-10.16Mn in the Q4 2019. On a quarterly growth basis, Stoke Therapeutics has generated -18.08% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Stoke Therapeutics post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Stoke Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.71 - a -4.41% fall from last quarter’s estimates.

EPS Estimate Current Year:

Stoke Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.71.

Key Ratios

Key ratios of the Stoke Therapeutics post its Q3 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)


Earning Per Share (EPS):

Stoke Therapeutics’s earning per share (EPS) fell -8.2% since last year same period to -0.66 in the Q3 2022. This indicates that the Stoke Therapeutics has generated -8.2% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Stoke Therapeutics’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Stoke Therapeutics’s return on equity (ROE) stands at -0.45.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Stoke Therapeutics
45 Wiggins Avenue, Bedford, MA, United States, 01730
Health Technology
Edward Kaye

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*